NASDAQ
02.01.26 | 19:28
79,98 US-Dollar
-2,32 % -1,90
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11.25 | Mizuho initiates coverage on Tarsus Pharmaceuticals stock with Outperform rating | 1 | Investing.com | ||
| 20.11.25 | Mizuho startet Coverage für Tarsus Pharmaceuticals mit "Outperform" und 30 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 18.11.25 | Aktie von Tarsus Pharmaceuticals klettert auf Rekordhoch von 76,85 USD | 2 | Investing.com Deutsch | ||
| 05.11.25 | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | 2 | Seeking Alpha | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Tarsus Q3 2025 presentation slides: XDEMVY sales surge 147% YoY to $118.7M | 2 | Investing.com | ||
| 04.11.25 | Tarsus Q3 2025: XDEMVY-Umsatz schnellt um 147 % auf 118,7 Mio. US-Dollar in die Höhe | 1 | Investing.com Deutsch | ||
| 04.11.25 | Tarsus Pharmaceuticals: Umsatz und Ergebnis übertreffen Prognosen für Q3 2025 | 2 | Investing.com Deutsch | ||
| 04.11.25 | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | 196 | GlobeNewswire (Europe) | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| 04.11.25 | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10.25 | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 20.10.25 | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | 10 | Investing.com | ||
| 07.08.25 | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 3 | Seeking Alpha | ||
| 06.08.25 | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 567 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| 06.08.25 | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08.25 | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07.25 | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 01.05.25 | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 888 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| 13.01.25 | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | 937 | GlobeNewswire (Europe) | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,522 | +1,32 % | Evotec-Aktie: Könnte schon bald die 0 Euro vorm Kurs stehen? | © Foto: fn SymbolbildDer Hamburger Biotech-Konzern Evotec taumelt. Die Aktie notiert noch knapp über der 5-Euro-Marke, aber nur wenige Cent vom Jahrestief entfernt. Gleichzeitig verkauft der Forschungsvorstand... ► Artikel lesen | |
| MODERNA | 26,100 | -1,73 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VIKING THERAPEUTICS | 30,115 | -3,45 % | Viking Therapeutics-Aktie: Hopp oder top? | Die Aktie von Viking Therapeutics steht exemplarisch für die enorme Dynamik im Markt für Abnehmmedikamente und spiegelt zugleich die noch ungelösten Bewertungsfragen im Biotech-Sektor wider. Trotz deutlicher... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| KUROS BIOSCIENCES | 29,860 | +0,27 % | Kuros Biosciences AG: Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion | Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
Schlieren (Zürich), Switzerland,... ► Artikel lesen | |
| ABIVAX | 115,20 | -4,64 % | How Abivax (ABVX) Turned Heads With Whopping 1700% Surge in 2025 | ||
| MINDMAZE THERAPEUTICS | 2,170 | -1,81 % | MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
23.12.2025... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,221 | -6,37 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| DENALI THERAPEUTICS | 13,735 | -3,44 % | Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence | ||
| CYTOMX THERAPEUTICS | 3,694 | +3,71 % | CytomX-Aktie nach +1.000% - was jetzt? | Unser Community-Dauerbrenner CytomX Therapeutics hat sich seit unserem letzten Update Anfang Oktober weiter hervorragend entwickelt, konnte sich innerhalb eines Jahres mittlerweile verzehnfachen. Ist... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,982 | +0,24 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | ||
| SYNDAX PHARMACEUTICALS | 18,400 | +2,79 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update | - $45.9 million in total revenue, representing 21% growth over 2Q25 - - $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting... ► Artikel lesen | |
| ASCENDIS PHARMA | 183,00 | +1,67 % | Ascendis Pharma: Grundkapitalerhöhung nach Ausübung von Optionsscheinen | ||
| JASPER THERAPEUTICS | 1,820 | -0,55 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation | Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 1,720 | +2,99 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology | - New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial- TEL AVIV... ► Artikel lesen |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,32 % bei einem Aktienkurs von 79,98 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.